Semaglutide · benefits
Semaglutide benefits: what is actually demonstrated
The documented benefits of approved semaglutide — weight, metabolic, and cardiovascular — and why a microdose doesn't inherit them.
At approved doses, semaglutide's demonstrated benefits are weight loss and, for the approved product, metabolic improvements and cardiovascular risk reduction (SELECT). These benefits are documented for the approved single GLP-1 receptor agonist at its labeled dose — not for compounded or microdose versions, which have no such outcome evidence.
Benefits shown in approved-product trials
| Benefit | What the evidence shows |
|---|---|
| Weight loss | ~14.9% mean reduction at the approved dose in STEP 1. |
| Waist circumference & metabolic markers | Improvements in waist circumference, blood pressure, and glycemic markers accompany weight loss in the trials. |
| Glycemic control | The same molecule is approved for type 2 diabetes, where it lowers HbA1c. |
| Cardiovascular risk | About a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, without diabetes (SELECT). |
Why these do not automatically apply to a microdose
Every benefit above was measured at the approved labeled dose. A deliberate microdose delivers less drug, and there is no trial showing the same benefits at a sub-therapeutic dose. Assuming a microdose yields proportional or equal benefit is an extrapolation the evidence does not support.
An approved oral semaglutide exists (Rybelsus), but it is a specifically engineered tablet using an absorption enhancer (SNAC) and is approved for type 2 diabetes, not weight management. A compounded 'oral', sublingual, ODT, or troche semaglutide is a different, unapproved product and does not inherit Rybelsus's evidence or its absorption engineering.
What the evidence shows
- Approved semaglutide improves weight and metabolic markers at labeled doses.
- SELECT showed cardiovascular benefit for the approved product.
What the evidence does not show
- That a compounded semaglutide microdose delivers these benefits.
- That benefits scale predictably down to sub-therapeutic doses.
Frequently asked questions
What are the proven benefits of semaglutide?
Weight loss (~14.9% at the approved dose), metabolic improvement, and cardiovascular risk reduction, all for the approved product.
Does a semaglutide microdose give the same benefits?
Unproven. Benefits are documented at approved doses; a microdose has no comparable outcome evidence.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.